- Prev close
- $64.81
- Day range
- $66.00 – $67.09
GEHC finished -0.9% on a quiet tape while the S&P 500 fell -0.4% and the Nasdaq 100 was +0.0%; the move looks more stock-specific than market-led, but the underlying business still shows mid-single-digit growth and solid margins. The StarGuide GX 4D SPECT/CT FDA 510(k) submission is a constructive product event, though earnings growth is still negative.
GEHC
GE HEALTHCARE TECHNOLOGY
As of Sep 16, 2026
62/100
Worth keeping an eye onHealth ScoreWhat drove the move
GEHC moved -0.9% even as the S&P 500 fell -0.4% and the Nasdaq 100 was +0.0%, so the session does not look like a broad market excuse. With no sector-peer move given, the clean read is stock-specific: the shares faded from an open of $64.09 to a close of $63.49 after a high of $64.46 and a low of $63.28, which is a mild intraday reversal rather than a disorderly break. The main company event in the facts is the StarGuide GX 4D SPECT/CT 510(k) submission, a positive development, but it did not translate into a stronger close.
Volatility vs. fundamentals
This looks like ordinary trading noise, not a fundamentals break. Revenue is still up 0.9% YoY (TTM) and 5.8% YoY in the latest quarter, with gross margin at 39.5%, operating margin at 12.9%, and net margin at 9.3%; that is a durable operating profile. The valuation is not cheap enough to cushion every dip, with PE 14.6 and forward PE 13.5, while beta 0.86 suggests the stock is typically a bit less volatile than the market. PEG 2.30 is not meaningful here because EPS growth is -11.0% YoY (TTM), so the better takeaway is that earnings are contracting even as sales and margins remain intact. On that mix, a -0.9% session is well within normal volatility and not evidence of deteriorating business health.
Earnings setup
The next earnings date is not available this period, so I cannot anchor the preview to a confirmed report date. The market-facing numbers in the facts point to revenue growth of 6.5% YoY (TTM) and 5.8% YoY in the latest quarter, with EPS at -11.0% YoY (TTM), gross margin at 39.5%, operating margin at 12.9%, and net margin at 9.3%. There is no prior post-earnings reaction history in the facts, so the focus stays on three items: whether the company can keep revenue growing in the mid-single digits, whether margins hold near 39.5% gross and 12.9% operating, and whether the StarGuide GX 4D SPECT/CT FDA 510(k) path shows up as a clearer U.S. growth driver.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track GEHC with WhyIHold
Get a plain-English explanation the next time GE HEALTHCARE TECHNOLOGY makes a big move — so you know whether it's benign or worth your attention.